ACADIA Pharmaceuticals Inc. Depreciation/Fixed assets

Depreciation/Fixed assets of ACAD for past 10 years: annual, quarterly and twelve month trailing (TTM) including Depreciation/Fixed assets growth rates and interactive chart.


Highlights and Quick Summary

  • Annual Depreciation/Fixed assets for 2020 was 0.05 (a -76.16% decrease from previous year)
  • Annual Depreciation/Fixed assets for 2019 was 0.22 (a -76.03% decrease from previous year)
  • Annual Depreciation/Fixed assets for 2018 was 0.91 (a -10.9% decrease from previous year)
  • Twelve month Depreciation/Fixed assets ending March 30, 2021 was 0.05 (a 1.93% increase compared to previous quarter)
  • Twelve month trailing Depreciation/Fixed assets decreased by -26.93% year-over-year
Trailing Depreciation/Fixed assets for the last four month:
30 Mar '21 30 Dec '20 29 Sep '20 29 Jun '20
0.05 0.05 0.04 0.07
Visit stockrow.com/ACAD for comprehensive keystats, realtime prices, income statement, balance sheet, cash flow statement with 10 years of data, and state-of-the-art screener.

Historical Depreciation/Fixed assets of ACADIA Pharmaceuticals Inc.

Most recent Depreciation/Fixed assetsof ACAD including historical data for past 10 years.

Interactive Chart of Depreciation/Fixed assets of ACADIA Pharmaceuticals Inc.

ACADIA Pharmaceuticals Inc. Depreciation/Fixed assets for the past 10 Years (both Annual and Quarterly)

Year Q1 Q2 Q3 Q4 Fiscal Year
2020 0.05
2019 0.22
2018 0.91
2017 1.02
2016 0.59
2015 -0.64
2014 1.25
2013 2.78
2012 -0.57
2011 2.58
2010 1.15

Business Profile of ACADIA Pharmaceuticals Inc.

Sector: Healthcare
Industry: Biotechnology
ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of small molecule drugs that address unmet medical needs in central nervous system disorders. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis; Trofinetide, a novel synthetic analog for the treatment of Rett syndrome; ACP-044, a novel first-in-class orally administered non-opioid analgesic for treating acute and chronic pain; and ACP-319, a positive allosteric modulator of the muscarinic receptor for treating cognition and schizophrenia. It is also developing pimavanserin as a treatment for dementia-related psychosis and as an adjunctive treatment for schizophrenia; and pimavanserin as an adjunctive treatment for major depressive disorder. ACADIA Pharmaceuticals Inc. was founded in 1993 and is headquartered in San Diego, California.